Treace Medical Concepts, Inc. (TMCI)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
TMCI Chart
People also search for
Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript
Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript
Treace Medical Concepts Q2 Earnings Call Highlights
Treace Medical Concepts NASDAQ: TMCI reported second-quarter 2026 revenue of $45.4 million, down 4% from the prior-year period, as lower procedure-kit sales to stocking distributors and a continued shift toward lower-priced minimally invasive products weighed on reported sales.
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.28 per share a year ago.
Treace Medical Concepts, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 44 | $59 | $208.56 | $149.56 | 253.49% |
 Anthony Scaramucci SkyBridge Capital II LLC | 6.36M | $56.03M | $30.48M | -$25.54M | -45.59% |
 Richard Slavik Newbridge Financial Services Group Inc. | 1,352 | $17,238 | $6,476.08 | -$10,761.92 | -62.43% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 91 | $121.94 | $392.21 | $270.27 | 221.64% |
 Rekah Franca Catalyst Funds Management Pty Ltd. | 28,800 | $114,624 | $136,800 | $22,176 | 19.35% |
Treace Medical Concepts, Inc. (TMCI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Treace Medical Concepts, Inc. ever had a stock split?
Treace Medical Concepts, Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | John T. Treace CEO | NASDAQ (NGS) Exchange | 89455T109 CUSIP |
| US Country | 450 Employees | - Last Dividend | - Last Split | 23 Apr 2021 IPO Date |
Overview
Treace Medical Concepts, Inc. is a pioneering medical technology firm based in the United States, specifically headquartered in Ponte Vedra, Florida. Founded in 2013, the company has dedicated itself to the design, manufacture, and marketing of innovative medical devices aimed at improving surgical outcomes. Treace Medical Concepts focuses on addressing foot and ankle conditions, with a strong emphasis on correcting bunion deformities. By leveraging advanced surgical techniques and state-of-the-art medical devices, the company seeks to redefine the standard of care for patients suffering from these conditions.
Products and Services
- Lapiplasty 3D Bunion Correction System
This revolutionary system is at the forefront of Treace Medical Concepts' product line, offering a comprehensive solution for surgically correcting bunions across three dimensions of deformity. It combines precision-engineered instruments, specialized implants, and an innovative surgical approach to achieve more predictable and durable outcomes than traditional bunion surgeries.
- Lapiplasty Mini-Incision System
Building on the success of their flagship Lapiplasty system, this mini-incision system is designed to facilitate the Lapiplasty procedure through a significantly smaller, 3.5-cm incision. This minimally invasive approach aims to reduce post-operative scarring, accelerate recovery times, and minimize patient discomfort while maintaining the effectiveness of the traditional Lapiplasty procedure.
- Adductoplasty System
The Adductoplasty system represents Treace Medical Concepts' commitment to addressing a broader range of foot deformities. It is specifically engineered for the reproducible realignment, stabilization, and fusion of the midfoot. By offering a tailored solution for midfoot conditions, the Adductoplasty system underscores the company's dedication to comprehensive foot and ankle care.
